Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Capital Market and Proxy Notes

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon May 02, 2021 10:14pm

91 Views

Post# 33112172

RE:RE:RE:RE:RE:Capital Market and Proxy Notes

My thoughts exactly.

stockman75 wrote: I lean toward this view. I was not a huge fan of the response. It seemed a bit placating and lacked details which I would have liked to have heard. Would have liked a bit more humility and not sure of the full sincerity. I know it is hard fully admitting failure. But we all know the team has failed miserably in getting proper valuation. For me this comes down to trust and confidence in the board. I am not so sure about the "now things are changing"... really what a coincidence. Bit of a song and dance. At this point they don't have my full trust based on all the information. Feel free to convince me I am wrong. I will listen.

palinc2000 wrote: Wino
You deserve a lot of credit for the time you spent on this task of representing a lot of shareholders and reporting back .Your highly professional way in the way you approached and carried out your discussion with the Chairwoman and the CeO is noteworthy.

I gather that they agreed to this meeting on the condition that you submit your questions a week in advance...I sense that some if not most of the answers are really just politically correct and aimed at not getting any nominee (s)
on the Slate rejected by shareholders that you represent...
I am not sure that we should just simply give them a free pass
My proposal would be for you to be allowed to ask questions at all Q&A periods during CC s where analysts are invited .... You would be the sole judge of which questions to ask and not be bound by allegiance to this Stockhouse MB....
If the Company agrees formally or informally before the deadline to submit the Proxys to allow you to ask questions LIVE then I think we could give them a free pass on the Slate .Otherwise I think we should proceed as planned and vote to remove one or more nominees.

Sent from my iPhone